Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
EDITAS MEDICINE INC (EDIT) Stock Price & Overview
NASDAQ:EDIT • US28106W1036
Current stock price
2.82 USD
-0.24 (-7.84%)
At close:
2.7938 USD
-0.03 (-0.93%)
After Hours:
The current stock price of EDIT is 2.82 USD. Today EDIT is down by -7.84%. In the past month the price increased by 14.17%. In the past year, price increased by 71.95%.
EDIT Key Statistics
52-Week Range1.29 - 4.5372
Current EDIT stock price positioned within its 52-week range.
1-Month Range2.5 - 3.65
Current EDIT stock price positioned within its 1-month range.
- Market Cap
- 275.993M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.89
- Dividend Yield
- N/A
EDIT Stock Performance
Today
-7.84%
1 Week
-15.32%
1 Month
+14.17%
3 Months
+41.71%
Longer-term
6 Months -8.44%
1 Year +71.95%
2 Years -45.87%
3 Years -65.44%
5 Years -92.38%
10 Years -91.47%
EDIT Stock Chart
EDIT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EDIT. When comparing the yearly performance of all stocks, EDIT is one of the better performing stocks in the market, outperforming 91.85% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
EDIT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EDIT. EDIT may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EDIT Earnings
On March 9, 2026 EDIT reported an EPS of -0.06 and a revenue of 24.74M. The company beat EPS expectations (77.22% surprise) and beat revenue expectations (333.52% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateMar 9, 2026
PeriodQ4 / 2025
EPS Reported-$0.06
Revenue Reported24.741M
EPS Surprise 77.22%
Revenue Surprise 333.52%
EDIT Forecast & Estimates
20 analysts have analysed EDIT and the average price target is 5.52 USD. This implies a price increase of 95.68% is expected in the next year compared to the current price of 2.82.
For the next year, analysts expect an EPS growth of 44.29% and a revenue growth 24.19% for EDIT
Analysts
Analysts75
Price Target5.52 (95.74%)
EPS Next Y44.29%
Revenue Next Year24.19%
EDIT Index Membership
EDIT is currently included in the following stock indexes tracked on ChartMill.
EDIT Financial Highlights
Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS increased by 34.37% compared to the year before.
Income Statements
Revenue(TTM)40.52M
Net Income(TTM)-160.06M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.81% | ||
| ROE | -586.56% | ||
| Debt/Equity | 1.96 |
Chartmill High Growth Momentum
EPS Q2Q%89.09%
Sales Q2Q%-19.16%
EPS 1Y (TTM)34.37%
Revenue 1Y (TTM)25.4%
EDIT Ownership
Ownership
Inst Owners52.98%
Shares97.87M
Float97.61M
Ins Owners0.19%
Short Float %11.18%
Short Ratio6.4
EDIT Industry Overview
EDIT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
EDIT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EDIT
Company Profile
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Company Info
IPO: 2016-02-03
EDITAS MEDICINE INC
11 Hurley St
Cambridge MASSACHUSETTS 02141 US
CEO: James C. Mullen
Employees: 87
Phone: 16174019000
EDITAS MEDICINE INC / EDIT FAQ
Can you describe the business of EDITAS MEDICINE INC?
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
What is the current price of EDIT stock?
The current stock price of EDIT is 2.82 USD. The price decreased by -7.84% in the last trading session.
What is the dividend status of EDITAS MEDICINE INC?
EDIT does not pay a dividend.
What is the ChartMill technical and fundamental rating of EDIT stock?
EDIT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of EDIT stock?
EDITAS MEDICINE INC (EDIT) operates in the Health Care sector and the Biotechnology industry.
How many employees does EDITAS MEDICINE INC have?
EDITAS MEDICINE INC (EDIT) currently has 87 employees.
What is EDITAS MEDICINE INC worth?
EDITAS MEDICINE INC (EDIT) has a market capitalization of 275.99M USD. This makes EDIT a Micro Cap stock.